MTOR and neoplasm: Given our findings that NCAPH promotes the proliferation of PCa cells by activating multiple pathways, such as mTOR and cell cycle transition, we next aimed to investigate the synergistic anti-tumor effects of NCAPH in combination with the mTOR inhibitor Everolimus (Eve) (MedChemExpress, HY-10218) and the cyclin-dependent kinase inhibitor Flavopiridol (Flav) (MedChemExpress, HY-10005).